CoChat

Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors

Open access
Rivera, Barbara, Gayden, Tenzin, Carrot-Zhang, Jian, Nadaf, Javad, Boshari, Talia, Faury, Damien, Zeinieh, Michele, Blanc, Romeo, Burk, David L., Fahiminiya, Somayyeh, Bareke, Eric, Schüller, Ulrich, Monoranu, Camelia M., Sträter, Ronald, Kerl, Kornelius, Niederstadt, Thomas, Kurlemann, Gerhard, Ellezam, Benjamin, Michalak, Zuzanna, Thom, Maria, Lockhart, Paul J., Leventer, Richard J., Ohm, Milou, MacGregor, Duncan, Jones, David, Karamchandani, Jason, Greenwood, Celia M. T., Berghuis, Albert M., Bens, Susanne, Siebert, Reiner, Zakrzewska, Magdalena, Liberski, Pawel P., Zakrzewski, Krzysztof, Sisodiya, Sanjay M., Paulus, Werner, Albrecht, Steffen, Hasselblatt, Martin, Jabado, Nada, Foulkes, William D., Majewski, Jacek · 2016 · Acta Neuropathologica
Cited by 196

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Dysembryoplastic neuroepithelial tumor (DNET) is a benign brain tumor associated with intractable drug-resistant epilepsy. In order to identify underlying genetic alterations and molecular mechanisms, we examined three family members affected by multinodular DNETs as well as 100 sporadic tumors from 96 patients, which had been referred to us as DNETs. We performed whole-exome sequencing on 46 tumors and targeted sequencing for hotspot FGFR1 mutations and BRAF p.V600E was used on the remaining samples. FISH, copy number variation assays and Sanger sequencing were used to validate the findings. By whole-exome sequencing of the familial cases, we identified a novel germline FGFR1 mutation, p.R661P. Somatic activating FGFR1 mutations (p.N546K or p.K656E) were observed in the tumor samples and further evidence for functional relevance was obtained by in silico modeling. The FGFR1 p.K656E mutation was confirmed to be in cis with the germline p.R661P variant. In 43 sporadic cases, in which the diagnosis of DNET could be confirmed on central blinded neuropathology review, FGFR1 alterations were also frequent and mainly comprised intragenic tyrosine kinase FGFR1 duplication and multiple mutants in cis (25/43; 58.1 %) while BRAF p.V600E alterations were absent (0/43). In contrast, in 53 cases, in which the diagnosis of DNET was not confirmed, FGFR1 alterations were less common (10/53; 19 %; p < 0.0001) and hotspot BRAF p.V600E (12/53; 22.6 %) (p < 0.001) prevailed. We observed overexpression of phospho-ERK in FGFR1 p.R661P and p.N546K mutant expressing HEK293 cells as well as FGFR1 mutated tumor samples, supporting enhanced MAP kinase pathway activation under these conditions. In conclusion, constitutional and somatic FGFR1 alterations and MAP kinase pathway activation are key events in the pathogenesis of DNET. These findings point the way towards existing targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-016-1549-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 196

Metadata

Authors
Rivera, B., Gayden, T., Carrot-Zhang, J., Nadaf, J., Boshari, T., Faury, D., Zeinieh, M., Blanc, R., Burk, D. L., Fahiminiya, S., Bareke, E., Schüller, U., Monoranu, C. M., Sträter, R., Kerl, K., Niederstadt, T., Kurlemann, G., Ellezam, B., Michalak, Z., Thom, M., Lockhart, P. J., Leventer, R. J., Ohm, M., MacGregor, D., Jones, D., Karamchandani, J., Greenwood, C. M. T., Berghuis, A. M., Bens, S., Siebert, R., Zakrzewska, M., Liberski, P. P., Zakrzewski, K., Sisodiya, S. M., Paulus, W., Albrecht, S., Hasselblatt, M., Jabado, N., Foulkes, W. D., & Majewski, J.
Venue
Acta Neuropathologica
Published
2016-02-26
Volume
131
Issue
6
Pages
847-863
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2278537091
Cited by
196
References
3
FWCI
14.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.